ArticleTherapeutic advances in vaccines2013
Novel HIV vaccine strategies: overview and perspective.
Article in Therapeutic advances in vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years.Frontiers in immunology · 2023Pooled it
- Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes.The Journal of experimental medicine · 2019Trial
- Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.The Journal of infectious diseases · 2016Trial
- Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion.Science translational medicine · 2025Article
- The experience of trial participation disclosure among sex workers in a phase IIb HIV vaccine trial: A qualitative study in urban Tanzania.PLOS global public health · 2025Article
- HTLV-1 vaccination Landscape: Current developments and challenges.Vaccine: X · 2024Review
- HIV-1 Transmission Cluster in Injection Drug Users in Nairobi City, Kenya.Ethiopian journal of health sciences · 2023Article
- USP10 regulates B cell response to SARS-CoV-2 or HIV-1 nanoparticle vaccines through deubiquitinating AID.Signal transduction and targeted therapy · 2022Article
- Subcutaneous administration CpG-ODNs acts as a potent adjuvant for an HIV-1-tat-based vaccine candidate to elicit cellular immunity in BALB/c mice.Biotechnology letters · 2018Article
- Dendritic cell targeted HIV-1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8Immunity, inflammation and disease · 2018Article
- Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine.Journal of chemical technology and biotechnology (Oxford, Oxfordshire : 1986) · 2017Article
- M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures.Scientific reports · 2017Article
- Identification of HIV-1-Based Virus-like Particles by Multifrequency Atomic Force Microscopy.Biophysical journal · 2016Article
- Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.Cell · 2016Article
- Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy.Reviews in medical virology · 2016Review
- Future Challenges for Vaccinologists.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Review
- Human immunodeficiency virus vaccines.Infectious disease clinics of North America · 2014Review
- Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.Journal of virology · 2014Article
- Fcgbp - A Potential Viral Trap in RV144.The open AIDS journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A human immunodeficiency virus (HIV) vaccine remains a central component in the quest to control the worldwide epidemic. To examine the status of the development of HIV vaccines, we review the results of the efficacy trials carried out to date and the immunologic principles that guided them. Four vaccine concepts have been evaluated in HIV-1 vaccine efficacy trials, and the results of these trials have provided significant information for future vaccine development. While one of these trials demonstrated that a safe and effective HIV vaccine is possible, many questions remain regarding the basis for the observed protection and the most efficient way to stimulate it. Novel HIV vaccine strategies including induction of highly potent broadly neutralizing antibodies, use of novel homologous and heterologous vector systems, and vectored immunoprophylaxis seek to expand and build upon the knowledge gained from these trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.